Bevacizumab (Avastin): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

27 March 2024

24 March 2024

  • curprev 06:1206:12, 24 March 2024‎ Lazy talk contribs‎ 481 bytes +481‎ Created page with "{{TreatmentInfo |drug_name=Bevacizumab (Avastin) |FDA_approval=Yes, for recurrent glioblastoma |used_for=Glioblastoma |clinical_trial_phase=Phase III |common_side_effects=Hypertension, proteinuria, and hemorrhage |OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months |usefulness_rating=4 |notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence. |category=Other Chemotherapy and Cancer Dr..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Bevacizumab_(Avastin)"